HC Wainwright Forecasts Sutro Biopharma Q2 Earnings

Sutro Biopharma, Inc. (NASDAQ:STRO) – Equities researchers at HC Wainwright issued their Q2 2025 EPS estimates for Sutro Biopharma in a research note issued on Monday, November 18th. HC Wainwright analyst A. Fein anticipates that the company will earn ($0.87) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Sutro Biopharma’s current full-year earnings is ($2.89) per share. HC Wainwright also issued estimates for Sutro Biopharma’s Q4 2025 earnings at ($0.96) EPS.

A number of other equities analysts also recently weighed in on the company. JMP Securities reaffirmed a “market outperform” rating and issued a $17.00 target price on shares of Sutro Biopharma in a report on Monday, September 16th. Truist Financial decreased their target price on Sutro Biopharma from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, August 16th. Finally, Piper Sandler reissued an “overweight” rating and issued a $11.00 price target on shares of Sutro Biopharma in a report on Friday, October 11th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Sutro Biopharma presently has a consensus rating of “Buy” and an average price target of $12.14.

Sutro Biopharma Stock Performance

Shares of STRO stock opened at $2.67 on Tuesday. The company has a market capitalization of $220.17 million, a price-to-earnings ratio of -1.66 and a beta of 1.17. Sutro Biopharma has a 52-week low of $2.13 and a 52-week high of $6.13. The company has a 50-day simple moving average of $3.64 and a two-hundred day simple moving average of $3.81.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in STRO. Gladius Capital Management LP bought a new stake in Sutro Biopharma in the 3rd quarter valued at about $28,000. ProShare Advisors LLC lifted its stake in shares of Sutro Biopharma by 49.1% during the 2nd quarter. ProShare Advisors LLC now owns 16,316 shares of the company’s stock valued at $48,000 after buying an additional 5,373 shares in the last quarter. Virtu Financial LLC bought a new position in Sutro Biopharma in the 3rd quarter worth approximately $77,000. Intech Investment Management LLC purchased a new position in Sutro Biopharma in the 3rd quarter valued at approximately $91,000. Finally, Lazard Asset Management LLC bought a new stake in Sutro Biopharma during the 1st quarter valued at $92,000. Institutional investors own 96.99% of the company’s stock.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.